Moderna and MSD's Intismeran Reduces Melanoma Recurrence and Death Risk by 49%

Moderna and MSD's Intismeran Shows Significant Benefit in Melanoma

Moderna and MSD presented five-year follow-up data from their Phase IIb KEYNOTE-942 study at ASCO 2026, demonstrating significant benefits for their personalized mRNA cancer vaccine, intismeran, in combination with pembrolizumab for melanoma patients. The combination therapy reduced the risk of skin cancer recurrence or death by 49% and the risk of distant metastasis by 59%. After five years, 68.8% of patients on the combination remained cancer-free, compared to 49.1% for pembrolizumab alone. Overall survival was 92.2% for the combination group versus 71.3% for the immunotherapy-alone group, highlighting the potential of mRNA vaccines in oncology.

• The combination of intismeran and pembrolizumab demonstrated robust efficacy in melanoma, significantly reducing the risk of recurrence and death by 49% over five years. Patients receiving the combination therapy also experienced a 59% reduction in the risk of distant metastasis, indicating a substantial improvement in disease control compared to pembrolizumab monotherapy.
• Long-term follow-up data from the KEYNOTE-942 study showed superior cancer-free rates and overall survival for the combination arm. After five years, 68.8% of patients treated with intismeran plus pembrolizumab remained cancer-free, compared to 49.1% in the pembrolizumab-alone group. The overall survival rate reached 92.2% for the combination, significantly higher than the 71.3% observed with immunotherapy alone.
• Intismeran is a personalized immunotherapy strategy, custom-developed using information from each patient's individual tumor. This tailored approach, leveraging mRNA vaccine technology, shows promise for cancers with high mutation rates. Experts suggest these findings encourage further research into mRNA vaccines combined with immunotherapy for other difficult-to-target cancers.

Intismeran and Pembrolizumab: Significant Efficacy in Melanoma

Recent clinical studies have demonstrated promising advances in melanoma treatment across multiple therapeutic approaches. These studies span from large-scale real-world analyses to novel combination therapies, providing valuable insights into both safety profiles and therapeutic efficacy in diverse patient populations.

• ADOREG Registry (2013-2023): Retrospective multicenter study of 8,213 melanoma patients comparing outcomes between patients <75 years and ≥75 years receiving immunotherapy (anti-PD-1 monotherapy and combination immune checkpoint inhibitors). Safety outcomes showed lower toxicity rates in geriatric patients with balanced toxicity profiles for immunotherapy. Efficacy outcomes demonstrated no difference in treatment effectiveness between age groups (p=0.306), with progression-free survival and melanoma-specific survival remaining unimpaired in elderly patients (p>0.05).

• MELATORCH Trial (NCT03430297): Phase 3 randomized trial comparing toripalimab (PD-1 inhibitor) versus dacarbazine in 256 patients with advanced melanoma, predominantly acral subtype. Safety profile showed grade 3+ treatment-related adverse events in 28.3% of toripalimab patients, with increased lipase (8.7%) and anemia (3.9%) being most common. Efficacy results demonstrated 29.2% reduction in disease progression or death risk (HR 0.71, 95% CI 0.53-0.95, P=0.02) with objective response rates of 11.0% versus 8.6% for dacarbazine.

• RELATIVITY-098 Trial (NCT05002569): Phase 3 double-blind study of 1,093 patients with completely resected stage III/IV melanoma comparing adjuvant nivolumab plus relatlimab to nivolumab monotherapy. Safety data showed comparable tolerability between groups with standard immune checkpoint inhibitor adverse event profiles. Efficacy analysis revealed no difference in recurrence-free survival between combination therapy and monotherapy (HR=1.01, 95% CI 0.83-1.22, P=0.928).

• Chinese Nationwide Real-World Cohort (2018-2023): Retrospective study of 508 advanced melanoma patients across five treatment groups including PD-1 monotherapy and various combination regimens. Safety outcomes identified triple therapy (PD-1+IFN-α1b+TKI) as having highest risk of grade 3-5 immune-related adverse events (OR 3.1, 95% CI 1.2-8.1, p=0.019), while other combinations showed acceptable tolerability. The study concluded triple therapy is not recommended due to unfavorable risk-benefit ratio.

• Pembrolizumab with Anlotinib Study: Retrospective analysis of 41 patients with advanced oral mucosal melanoma treated between August 2018 and September 2024. Safety profile showed treatment-related adverse events in 80.5% of patients, predominantly hypertension (29.3%) and hand-foot syndrome (19.5%), with only 4.8% experiencing grade 3+ events and no grade 5 events. Efficacy outcomes demonstrated 41.4% objective response rate with median progression-free survival of 6.4 months and median overall survival of 10.0 months.

Evolving Melanoma Treatment Landscape and Intismeran's Potential Role

The melanoma treatment landscape has undergone dramatic transformation over the past five years, characterized by revolutionary advances in immunotherapy and targeted therapy that have fundamentally altered patient outcomes. Since 2011, the introduction of immune checkpoint inhibitors and MAPK pathway-targeted therapies has changed the natural history of this disease, with more than half of advanced melanoma patients now surviving beyond five years compared to previously dismal survival rates below 5%. The median overall survival has improved remarkably, increasing from 8.8 months in the 2004-2010 period to 25.9 months in the 2016-2020 period, while the proportion of patients not receiving systemic treatment decreased from 54.9% to 28.3% during the same timeframes.

Current treatment patterns demonstrate the dominance of combination approaches and precision medicine strategies. Real-world evidence from 2015-2018 shows that 45.3% of patients initiated first-line treatment with immunotherapy-based regimens while 53.3% received targeted therapy-based regimens, with the most common approaches being BRAF/MEK inhibitor combinations (31.6%), anti-PD-1 monotherapy (25.3%), and BRAF monotherapy (21.8%). Meta-analysis of recent randomized controlled trials encompassing 2,816 participants demonstrates that combined therapy with vemurafenib, cobimetinib, and ipilimumab achieved superior overall survival with an odds ratio of 6.95 compared to monotherapy, while dabrafenib and trametinib combination therapy showed improved outcomes with favorable tolerability profiles. Neoadjuvant immunotherapy has emerged as a particularly promising strategy, with meta-analysis of 451 patients showing pooled pathological complete response rates of 47%, leading to its adoption as the new standard of care for locoregionally advanced melanoma.

Despite these advances, significant challenges remain, with approximately 50% of patients still experiencing treatment failure due to primary or acquired resistance mechanisms. The current research focus has shifted toward novel combination strategies and emerging therapeutic modalities, with over 3,000 trials currently evaluating immunotherapeutic combinations targeting pathways including LAG-3, TIM-3, STING, and adenosine signaling. Recent developments include the integration of adoptive cell therapy approaches, oncolytic virotherapy, and innovative platforms such as therapeutic hydrogels for localized drug delivery. The field is also advancing toward comprehensive biomarker-driven patient stratification, integrating tumor mutational burden, inflammatory gene expression signatures, and BRAF mutation status to optimize treatment selection and overcome the limitations of current checkpoint inhibitor therapies.

Personalized mRNA Vaccine Delivers Enduring Melanoma Benefit

The five-year follow-up data from the KEYNOTE-942 study marks a significant milestone in the fight against high-risk melanoma, showcasing the profound and sustained impact of personalized mRNA cancer vaccines when combined with established immune checkpoint inhibitors. The combination of intismeran (mRNA-4157/V940) and pembrolizumab delivered impressive reductions in recurrence, distant metastasis, and a substantial improvement in overall survival compared to pembrolizumab alone. This outcome not only offers new hope for patients with resected high-risk melanoma but also fundamentally validates the therapeutic potential of mRNA technology in oncology.

Pembrolizumab, as demonstrated across numerous trials like KEYNOTE-042 in non-small cell lung cancer, has already revolutionized cancer treatment by enhancing anti-tumor immune activity. The current data suggests that a personalized mRNA vaccine can further amplify this effect by training the immune system to recognize specific neoantigens unique to a patient's tumor, leading to a more targeted and durable response. This personalized approach, leveraging a patient's individual mutational landscape, represents a powerful stride towards precision oncology.

However, the path to widespread adoption is not without its considerations. The individualized nature of mRNA-4157 implies inherent complexities in manufacturing and potentially higher costs, which will be critical factors for market access and reimbursement. While the safety profile was deemed manageable, the observed increase in Grade ≥3 treatment-related adverse events with the combination therapy warrants careful monitoring in larger populations. Furthermore, scaling the infrastructure required for rapid tumor sequencing, personalized vaccine production, and timely delivery will be a significant logistical challenge. Despite these hurdles, the compelling long-term efficacy data positions this combination as a potential new benchmark, paving the way for similar personalized immunotherapy strategies across a broader spectrum of cancers.